Alpha 1-Antitrypsin Deficiency Clinical Trial
Official title:
A Placebo-Controlled, Multi-dose, Phase 2 Study to Determine the Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency (AATD) [SEQUOIA]
The purpose of AROAAT2001 (SEQUOIA) is to evaluate the safety, efficacy and tolerability of multiple doses of the investigational product, Fazirsiran Injection, administered subcutaneously to participants with alpha-1 antitrypsin deficiency (AATD).
Participants will be enrolled to receive multiple subcutaneous injections of Fazirsiran Injection (also referred to as TAK-999 Injection or ARO-AAT Injection) or placebo. Eligible participants will require a pre-dose biopsy completed as part of the study within the screening window. However, any participant with a biopsy result within 1 year of screening showing no fibrosis does not require a pre-dose biopsy. Only participants who have liver fibrosis will undergo a post-dose biopsy and may continue treatment in an open-label phase. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05687474 -
Baby Detect : Genomic Newborn Screening
|
||
| Recruiting |
NCT03285100 -
The Effects of Discontinuation of Vitamin K Antagonists on the Rate of Elastin Degradation
|
N/A | |
| Completed |
NCT03636347 -
A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo.
|
Phase 2 | |
| Completed |
NCT00396006 -
Efficacy and Safety Study of Augmentation Therapy With ARALAST Fraction IV-1 (Human Alpha 1 - Proteinase Inhibitor)
|
Phase 4 | |
| Completed |
NCT04174118 -
Study of DCR-A1AT in Healthy Adult Volunteers
|
Phase 1 | |
| Completed |
NCT05579431 -
A Phase 1, First-in-human Study of VX-634
|
Phase 1 | |
| Recruiting |
NCT05856331 -
Study of INBRX-101 Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema
|
Phase 2 | |
| Suspended |
NCT00571272 -
Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC)
|
||
| Completed |
NCT02168686 -
Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) Deficiency
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04204252 -
Evaluate Efficacy and Safety of "Kamada-AAT for Inhalation" in Patients With AATD
|
Phase 3 | |
| Completed |
NCT00067756 -
4-PBA: Will it Increase the Level of Alpha 1-Antitrypsin(AAT) in Persons With AAT Deficiency?
|
Phase 2 | |
| Not yet recruiting |
NCT06389877 -
A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)
|
Phase 1/Phase 2 | |
| Completed |
NCT00295061 -
Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults
|
Phase 3 | |
| Completed |
NCT00001462 -
Characterization of the Pathobiology of Early Lung Destruction in Alpha 1-Antitrypsin Deficient Individuals
|
N/A | |
| Active, not recruiting |
NCT05297812 -
Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease
|
||
| Completed |
NCT03114020 -
Efficacy/Safety of HA Inhalation Solution for Hereditary Emphysema in Patients With Alpha-1 Antitrypsin Deficiency
|
Phase 2 | |
| Completed |
NCT00460096 -
Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in Individuals With Alpha-1 Antitrypsin Deficiency
|
Phase 2/Phase 3 | |
| Completed |
NCT00377416 -
Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin Deficiency
|
Early Phase 1 | |
| Terminated |
NCT00005098 -
Study of Genotype and Phenotype in Patients With Alpha 1-Antitrypsin Deficiency
|
N/A | |
| Completed |
NCT03362242 -
Study of ARO-AAT in Normal Adult Volunteers
|
Phase 1 |